Related Experiment Video
Updated: Jul 16, 2025
06:27
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
439
Glioma Response to IDH Inhibition: Real-World Experience
Rimas V Lukas1,2, Craig Horbinski2,3,4
1Department of Neurology, Northwestern University, Chicago, Illinois.
Abstract:
Treatment of IDH-mutated non-enhancing grade 2 and 3 diffuse gliomas with ivosidenib leads to reduction of tumor size when assessed via volumetric MRI. Isocitrate dehydrogenase inhibition has a therapeutic benefit in patients with these tumors. See related article by Kamson et al., p. 4863.
